

How to find us ?


Location

Bordeaux, France
CAPC Musée d'art contemporain de Bordeaux
Entrepôt 7, rue Ferrère
33000 Bordeaux




Contact

symposium2013@imn-bordeaux.org



Associated organizations



This activity is supported by an educational grant from Lilly USA, LLC

SYMPOSIA



Second Symposium

International Symposium on New Therapeutic Avenues in Parkinson's Disease and Related Disorders

Bordeaux University,
September 4 - 5, 2013

The objective of this meeting is to brainstorm and dialogue between international Parkinson's disease experts and representatives of leading healthcare companies and innovative biotech startups, to better understand the evolution of the therapeutic area (met versus unmet needs, clinical trial design, derisking translational development, emerging treatment challenges) and its strategic implications for the Healthcare industry.


The topics cover the most striking unmet treatment needs of our patients with the ambition to provide a cure for Parkinson's disease in the future. Each expert will give an interactive presentation where he will briefly review his topic, define meaningful surrogate markers for the design of future clinical trials and identify the most promising and innovative treatment avenues.



Grand Théâtre



CAPC
Musée d'art contemporain



Place de la Bourse

September 4, 2013

8:50 - 9:00 OPENING

P. Vigouroux, General Director of the University Hospital
Bordeaux, France

MORNING SESSION (9:00 - 12:10)

9:00 - 10:20

Preclinical models of PD (caveats of current models, translational potential and the place of new models)
Chairmen: M. Vila, Barcelona, Spain and S. Hunot, Paris, France

9:00 - 9:40 Mechanisms of cellular death in PD
S. Przedborski, New York, USA

9:40 - 10:20 New animal models of PD
E. Bezard, Bordeaux, France

10:20 - 10:50 *Coffee Break*

10:50 - 12:10

Progress in pathophysiology, pathogenesis and genetics of PD
Chairmen: P. Burbaud and E. Bezard, Bordeaux, France

10:50 - 11:30 The contribution of genetics to the identification of new treatment targets
A. Singleton, Bethesda, USA

11:30 - 12:10 Alpha-synuclein – what makes the origami bird unfold?
G. Petsko, Waltham, USA

12:10 - 13:30 *Lunch Break*

AFTERNOON SESSION (13:30-16:40)

13:30 - 14:50

Unmet needs and emerging treatment challenges in PD
Chairmen: D. Devos, Lille, France and F. Tison, Bordeaux, France

13:30 - 14:10 Motor and non-motor signs
A. Yarnall, Newcastle, UK

14:10 - 14:50 Disease modification and neuroprotection
W. Olanow, New York, USA

14:50 - 15:20 *Coffee Break*

15:20 - 16:40

Biomarkers
Chairmen: W. Meissner, Bordeaux, France and G. Petsko, Waltham, USA

15:20 - 16:00 CSF and plasma: will we succeed?
J. Zhang, Seattle, USA

16:00-16:40 Imaging biomarkers: red herring or real possibilities?
N. Pavese, London, UK

September 5, 2013

MORNING SESSION (9:00 - 12:45)

9:00 - 11:00

New design for clinical trials

Chairmen: W. Olanow, New York, USA and J. Ferreira, Lisbon, Portugal

9:00 - 9:40 Adaptive trial design
V. Dragalin, Cambridge, USA

9:40 - 10:20 Regulatory authorities: views of the European Medicines Agency
P. Balabanov, London, UK

10:20 - 10:45 *Coffee Break*

10:45 - 12:05

Critical issues for the success of clinical trials

Chairmen: F. Tison, Bordeaux, France and M.C. Rodriguez-Oroz, San Sebastian, Spain

10:45 - 11:25 The interest of well-defined cohorts for clinical POC studies
W. Meissner, Bordeaux, France

11:25 - 12:05 How to improve study enrollment?
J.C. Corvol, Paris, France

12:05 - 13:30 *Lunch Break*

AFTERNOON SESSION (13:30 - 15:50)

13:30 - 14:50

The industry perspective

Chairman: E. Bezard, Bordeaux, France

13:30 - 14:10 Scientific issues and challenges
K. Merchant, Indianapolis, USA

14:10 - 14:50 Economic strategy and decision making
T. Blackburn, Hoboken, USA

14:50 - 15:20

Funding of clinical trials – convergence of industry, academia and patient advocacy groups

S. Chowdhury, Michael J. Fox Foundation, New York, USA

15:20 - 15:50

Innovation forecasting through bibliometrics, patent landscaping and market analysis

P. Gorry, Bordeaux, France

15:50 - 16:30 **FAREWELL**

16:30 **End of the symposium**